U.S. markets closed
  • S&P 500

    3,363.00
    +27.53 (+0.83%)
     
  • Dow 30

    27,781.70
    +329.04 (+1.20%)
     
  • Nasdaq

    11,167.51
    +82.26 (+0.74%)
     
  • Russell 2000

    1,507.69
    +2.96 (+0.20%)
     
  • Crude Oil

    39.86
    +0.57 (+1.45%)
     
  • Gold

    1,890.90
    -4.60 (-0.24%)
     
  • Silver

    23.34
    -0.15 (-0.66%)
     
  • EUR/USD

    1.1734
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    0.6770
    +0.0320 (+4.96%)
     
  • GBP/USD

    1.2921
    +0.0061 (+0.47%)
     
  • USD/JPY

    105.4300
    -0.2250 (-0.21%)
     
  • BTC-USD

    10,732.11
    -112.10 (-1.03%)
     
  • CMC Crypto 200

    221.39
    -0.01 (-0.00%)
     
  • FTSE 100

    5,866.10
    -31.40 (-0.53%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

CVS Health Beats 2Q Estimates, Top Analyst Sticks To Hold

support@smarteranalyst.com (Ben Mahaney)

CVS Health reported better-than-expected 2Q earnings and raised its full-year guidance. The company is bullish on its diverse business, including its drugstore chain and health benefits, and believes that it is well-positioned to weather the impact of the coronavirus pandemic.

CVS Health (CVS) reported 2Q adjusted earnings of $2.64 per share, up from $1.89 per share in the year-ago period, and beating analysts’ estimates of $1.93 per share. Revenue during the reported quarter grew 3% to $65.3 billion year-on-year marginally higher than the Wall Street consensus of $64.2 billion.

For the full-year, the company raised its adjusted earnings guidance to $7.14- $7.27, from the earlier forecast of $7.04 -$7.17. CVS now expects full-year cash flow from operations to be between $11 billion-$11.5 billion, up from the previous guidance of $10.5 billion-$11 billion.

Oppenheimer analyst Michael Wiederhorn maintained a Hold rating on the stock saying: “The Retail segment softened after a robust end to Q1 ($1.06B vs OPCO/Street $1.15B/$1.34B) due to COVID-related impacts to op-expenses and volumes, while the Pharmacy segment ($1.33B vs. OPCO/Street $1.28B/$1.34B) was largely in-line, overcoming softer new prescriptions and incremental costs.”

Currently, the Street has a cautiously optimistic outlook on the stock. The Moderate Buy analyst consensus is based on 5 Buys and 4 Holds. The average price target of $74.71 implies an upside potential of about 15%. (See CVS stock analysis on TipRanks).

Related News:
Zimmer Biomet Slips 3.7% On 2Q Profit Decline
Fiverr Pops 18% In Pre-Market On Upbeat 2Q Earnings And Raised Outlook
Square’s 64% Revenue Spike Pushes Shares Up 9% In Pre-Market

More recent articles from Smarter Analyst: